- Funisitis, a condition characterized by inflammation of the connective tissue of the umbilical cord typically associated with intra-amniotic infection, is gaining attention due to its link to adverse neonatal outcomes including preterm birth and neonatal sepsis. As a result, it is becoming a key focus area in maternal-fetal health diagnostics and therapeutics across both developed and developing regions
- The escalating demand for effective diagnostic and therapeutic solutions for funisitis is primarily fueled by increasing awareness of prenatal care, advancements in infection detection technologies, and the growing burden of preterm complications globally
- North America dominated the funisitis market with the largest revenue share of 36.4% in 2024, supported by well-established healthcare infrastructure, higher healthcare spending, and early adoption of advanced diagnostic techniques. The U.S. remains the key contributor, driven by rising investments in perinatal care and strong clinical research support for early intervention strategies
- Asia-Pacific is expected to be the fastest-growing region in the funisitis market during the forecast period, propelled by improving access to maternal care services, increasing birth rates, rising government healthcare investments, and a growing focus on reducing neonatal mortality and morbidity
- The Antibiotics segment dominated the funisitis market with a revenue share of 62.3% in 2024, as they are the primary line of treatment to manage maternal and fetal infections. Broad-spectrum antibiotics are often administered prophylactically or therapeutically to reduce the risk of neonatal complications
